NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with Irish Pharmacist includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


ADVERTISMENT

ADVERTISMENT

Updates made to PrEP clinical guidelines

By Irish Pharmacist - 06th Jul 2022

clinical guidelines

Updated clinical guidelines on pre-exposure prophylaxis (PrEP) have been released, with expanded access to HIV prevention medication. 

According to a revised document, dated May 2022, the eligibility criteria were expanded to include people “likely to engage in condomless anal sex in the next three months”. 

Updates were also made to the criteria around renal monitoring; frequency of follow-up determined by potential exposure; and online STI/HIV testing options for stable patients. The guidance also sets out a 45-day window for HIV testing, where a repeat test will be performed after that period. 

Additionally, a new section was included on when post-exposure prophylaxis following sexual exposure is needed in people taking PrEP. 

According to a spokesperson for the HSE, the updated guidance “will reduce the number of renal monitoring blood tests and face-to-face consultations for some individuals”. 

They added: “The updated guidance also allows for a greater degree of flexibility in determining an individual’s eligibility for PrEP.” The guidelines are set for review in May 2024 and “will be updated in the meantime should the need arise,” a HSE spokesperson commented. 

The first set of national clinical guidance on PrEP was published in November 2019. 

Currently, licensed PrEP is the pre-emptive use of oral antiretroviral therapy (combination tenofovir disoproxil fumarate/emtricitabine) by HIV-negative people to reduce the risk of HIV infection. In 2019, HIQA concluded a health technology assessment on the introduction of a PrEP programme in Ireland. HIQA found that PrEP was safe and highly effective at preventing HIV in people at substantial risk. 

Furthermore, implementing a PrEP programme would be considered cost-saving compared to standard care. Ireland began implementation of a national PrEP programme in November 2019, with ring-fenced funding of €5.4 million in Budget 2020. 

During 2020 and 2021, there was a reduction in the number of HIV notifications, according to the Health Protection Surveillance Centre. This was likely to be due to several factors, including periods of national lockdown; social and physical distancing measures; reduced access to sexual health and GP services; and reduced testing opportunities.

ADVERTISMENT

Latest

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

Latest Issue

Irish Pharmacist June 2024

Irish Pharmacist June 2024. Volume 25 | Issue 6 | June 2024. Read the latest issue of Irish Pharmacist here…

Read

OTC Update Spring 2024

Spring 2024 | Issue 1 | Volume 18. Read the latest issue of OTC Update here.

Read

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT